LG Chem 
Welcome,         Profile    Billing    Logout  
 39 Products   109 Diseases  39 Products   42 Trials   2017 News 
49 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fotivda (tivozanib) / LG Chem
2021-000050-26: Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Estudio para comparar Tivozanib en combinación con Nivolumab con Tivozanib en monoterapia en sujetos con carcinoma de células renales

Not yet recruiting
3
326
Europe, RoW
Tivozanib, Nivolumab, AV-951, Capsule, hard, Concentrate for solution for infusion, FOTIVDA®, OPDIVO
AVEO Pharmaceuticals, Inc., AVEO PHARMACEUTICALS, INC., AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma Carcinoma de Células Renales, Kidney cancer Cáncer de riñón, Diseases [C] - Cancer [C04]
 
 
TiNivo-2, NCT04987203 / 2021-000050-26: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Active, not recruiting
3
343
Europe, Canada, US, RoW
Tivozanib, Nivolumab
AVEO Pharmaceuticals, Inc., Parexel, Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
07/26
STRIKE, NCT06661720: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Recruiting
3
1040
US
Pembrolizumab, Keytruda, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, CT Scan, CAT Scan, Biopsy, Questionnaire Administration
Alliance for Clinical Trials in Oncology
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
11/37
11/37
NCT01885949: Tivozanib + Enzalutamide in Adv Prostate Cancer

Active, not recruiting
2
5
US
Tivozanib, AV-951, Enzalutamide, MDV-3100
Massachusetts General Hospital, National Comprehensive Cancer Network
Prostate Cancer
12/25
06/26
FORTUNE, NCT06053658: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Recruiting
2
48
US
Tivozanib, KRN 951, KRN-951, KRN951, UNII-172030934T, AV951, AV951 cpd, Nivolumab, Opdivo, BMS-936558
M.D. Anderson Cancer Center, AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
11/26
11/28
DEDUCTIVE, NCT03970616: A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Checkmark 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Jan 2022 - Jan 2022: 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Hourglass Jan 2021 - Dec 2021 : Data from P2 portion of P1b/2 DEDUCTIVE trial in combination with Imfinzi for advanced HCC
Hourglass Jul 2021 - Dec 2021 : Completion of enrollment of P2 portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC
Checkmark Data from P1b portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC at ASCO GI 2021
More
Terminated
1b/2
27
US
Tivozanib, Fotivda, Durvalumab, Imfinzi
AVEO Pharmaceuticals, Inc., AstraZeneca
Hepatocellular Carcinoma
04/23
04/23
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
06/25
06/26
NCT04645160: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Recruiting
1/2
31
US
Tivozanib
National Cancer Institute (NCI)
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
12/26
12/27
Gemiglo (gemigliptin) / Sanofi, LG Chem
NCT05194592: Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Recruiting
4
122
RoW
Dapagliflozin, Gemigliptin
Wonju Severance Christian Hospital
Type2 Diabetes, Remodeling, Ventricular
12/24
06/25
NCT03842267: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)

Completed
3
315
RoW
Gemigliptin 50mg, Gemigliptin Placebo
LG Chem
Diabetes Mellitus, Type 2
05/21
11/22
ficlatuzumab (AV-299) / LG Chem
FIERCE-HN, NCT06064877: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting
3
410
Europe, Canada, US, RoW
Ficlatuzumab, AV-299, Cetuximab, Erbitux, Placebo
AVEO Pharmaceuticals, Inc.
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
08/27
11/27
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

No Longer Available
N/A
US
ficlatuzumab, AV-299, SCH 900105
AVEO Pharmaceuticals, Inc.
Mullerian Mixed Tumor of Ovary
 
 
TNFcept (etanercept biosimilar) / LG Chem, Mochida
RECAST, NCT05164198: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis

Not yet recruiting
4
448
NA
Adalimumab and its biosimilars, Humira, Adaloce, Biological: Etanercept and its biosimilars, Enbrel, Eucept, Etalace, Golimumab, Simponi, Infliximab biosimilar, Remsima
Hanyang University Seoul Hospital, Linical Korea
Ankylosing Spondylitis, Axial Spondyloarthritis
10/24
10/24
NCT04449224: Comparative Effectiveness of Targeted Therapy in RA Patients

Recruiting
N/A
506
RoW
Adalimuab, Etanercept, Tocilizumab, or Abatacept, Humira, Enbrel, Etoloche, Eucept, Actemra, or Orencia, Tofacitinib or Baricitinib, Xeljanz or Olumiant
Hanyang University, Ministry of Health, Republic of Korea
Rheumatoid Arthritis
08/23
08/24
Besivo (besifovir) / Gilead, LG Chem, Ildong
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT03642340: A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

Recruiting
N/A
3000
RoW
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis b
05/23
08/23
Follitrope (recombinant human follicle stimulating hormone) / LG Chem
NCT06921395: Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

Recruiting
4
248
RoW
Fang Le Shu (Follitrope), Guo Na Fen (Gonal-F)
LG Chem
Female Infertility
09/25
06/26
MSP-IVC, NCT01058252: Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF

Recruiting
N/A
30
RoW
INVOCell, Letrozole 2.5 mg, recFSH 75 IU, Aromek (Letrozole 2.5 mg);, Follitrope (Recombinent FSH - 75 IU), IVF-C 5000 IU (HCG), Ova-Surge (Urinary LH Surge Kit), Indomethacin 50 mg, STEP-3: LH Suppression & Monitoring, STEP-4: HCG Timing, IVF-C 5000 IU, STEP-5: OPU, ET, Cancellation, Ovum Pick-Up, Embryo Transfer, Ultrasound Guided, INVOCell (Intravaginal Culturing), INVOCell, Diaphragm (Retention Device)
Galaxy Pharma (Pvt) Limited, Ova IVF & Reproductive Health Clinics, Karachi
Primary Infertility, Secondary Infertility, Low Responders, Mild to Moderate Male Factor Infertility
12/21
03/22
Euforvac (DTwP-HepB) / LG Chem
NCT06413121: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Recruiting
3
1557
RoW
Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV, Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Serum Institute of India Pvt. Ltd.
Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus Influenzae Type B Immunization, Polio Immunization
08/25
05/26
NCT05457946: Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Not yet recruiting
2/3
1438
NA
LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)
LG Chem
Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection
09/25
09/25
NCT06690515: Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

Not yet recruiting
1/2
465
RoW
DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A, DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B, Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®
PT Bio Farma, Faculty of Medicine Universitas Padjadjaran
Vaccine Adverse Reaction, Vaccine Reaction
10/25
09/26
rilogrotug (AV-380) / LG Chem
NCT04815551: A Phase 1 Study of AV-380 in Healthy Subjects

Completed
1
51
US
AV-380, Placebo
AVEO Pharmaceuticals, Inc.
Cachexia
01/22
01/22
NCT05865535: A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Recruiting
1
30
US
AV-380
AVEO Pharmaceuticals, Inc.
Cachexia
12/25
06/26
ZemiSU (gemigliptin/glimepiride) / LG Chem
NCT05663736: Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

Recruiting
4
80
RoW
Gemigliptin, Zemiglo, Glimepiride
Seoul National University Bundang Hospital
Ejection Fraction
10/23
12/23
CUE-101 / Cue Biopharma, LG Chem
NCT04852328: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Recruiting
2
30
US
CUE-101
Washington University School of Medicine, Cue Biopharma
Oropharyngeal Squamous Cell Carcinoma
10/27
10/27
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
01/26
01/26
Hyruan Plus (sodium hyaluronate) / LG Chem
NCT06437054: Verification of the Efficacy/safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss

Not yet recruiting
1/2
26
NA
Dexamethasone, Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm], Hyaluronic acid, Hyruan Plus Inj (Sodium Hyaluronate 10.0mg) [LG Chem], Indocyanine green(ICG), Cellbiongreen Inj (IndocyanineGreen 25mg) [Cellbion]
Seoul National University Hospital
Hearing Loss, Sensorineural, Hearing Loss, Sudden, Intratympanic Injection
02/26
09/28
Hyruan (sodium hyaluronate) / LG Chem
NCT05220527: Effects of Knee Injections on Patients With Knee Osteoarthritis

Enrolling by invitation
4
60
RoW
Triamcinolone plus hyruan, corticosteroids plus hyaluronic acid, vitagen plus hyruan, dextrose plus hyaluronic acid, normal saline plus hyruan, normal saline plus hyaluronic acid
Taipei Medical University, Shin Kong Wu Ho-Su Memorial Hospital
Knee Osteoarthritis, Injection, Effect of Drug
07/22
07/22
PDC*lung / PDC line Pharma
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
tigulixostat (LC350189) / LG Chem
EURELIA1, NCT05586958: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

Recruiting
3
350
US
Tigulixostat, LC350189, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
12/24
06/25
EURELIA2, NCT05586971: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed
3
2202
US
Tigulixostat, LC350189, Allopurinol, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
05/25
05/25
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed
2
84
RoW
Febuxostat, IBI128
Innovent Biologics (Suzhou) Co. Ltd.
Gout, Hyperuricemia
12/24
01/25
NCT06189404: Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Completed
1
24
US
Tigulixostat, LC350189, Theophylline
LG Chem
Gout, Hyperuricemia
11/23
11/23
NCT06277752: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Completed
1
30
RoW
dose-5 group, dose-1 group, dose-2 group, dose-4 group, dose-3 group
Innovent Biologics (Suzhou) Co. Ltd.
Gout Arthritis
03/24
03/24
GEN-001 / Genome & Company
GEN001-201, NCT05419362: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Active, not recruiting
2
42
RoW
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/24
KEYNOTE-D86, NCT05998447: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Recruiting
2
148
RoW
GEN-001, Pembrolizumab, KEYTRUDA®, mFOLFOX
Genome & Company, Merck Sharp & Dohme LLC
Biliary Tract Cancer
10/26
10/26
NCT04601402: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Completed
1
11
US
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany, Pfizer
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
01/23
01/23
NCT05079503: Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Not yet recruiting
N/A
40
NA
GEN-001, Lactococcus lactis
Korean Cancer Study Group
Locally Advanced Rectal Cancer
08/23
01/24
CUE-102 / Cue Biopharma
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT06917885: CUE-102 in Recurrent Glioblastoma

Recruiting
1
18
US
CUE-102
David Reardon, MD, Cue Biopharma
Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
01/26
01/27
LR19122 / LG Chem
NCT06947499: A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Recruiting
2/3
1186
RoW
LBVD, Pentavalent vaccine and Inactivated Polio vaccine
LG Chem
Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b
11/26
04/27
Euvax B (recombinant hepatitis B vaccine) / LG Chem
COMBAT-HBV, NCT05705427: The COMBAT HBV Feasibility Trial

Recruiting
4
560
RoW
Tenofovir Disoproxil Fumarate 300 MG, Viread, Hepatitis B monovalent vaccine, Hepatitis B birth-dose vaccine, Engerix-B, Placebo
University of North Carolina, Chapel Hill, Doris Duke Charitable Foundation, Université Protestant au Congo, Abbott, Albert Einstein College of Medicine
Hepatitis B, Vertical Transmission of Infectious Disease
08/25
08/25
MIT-001 / MitoImmune Therap
Capella, NCT05493800: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

Active, not recruiting
2
60
RoW
MIT-001, normal saline, placebo
MitoImmune Therapeutics
Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
06/24
12/24
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Active, not recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
12/25
12/25
NCT05389696: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

Completed
1
40
RoW
Single subcutaneous administration and Blood collection, MIT-001 10mg and 20mg, Single subcutaneous administration and then IV injection., MIT-001 40mg, MIT-001 20mg and 40mg_Multiple administration, MIT-001 20mg and 40mg
MitoImmune Therapeutics
Heathly Subjects
02/23
04/23
ICM-203 / Yonsei Technology Holdings
NCT04875754: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

Active, not recruiting
1/2
16
RoW
ICM-203, Placebo
ICM Biotech Australia Pty Ltd.
Osteoarthritis, Knee
03/26
12/26
NCT05454566: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Not yet recruiting
1/2
18
NA
ICM-203
ICM Co. Ltd.
Osteoarthritis, Knee
05/26
11/27
NCT05752032: A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Enrolling by invitation
N/A
16
RoW
ICM-203, Placebo
ICM Co. Ltd.
Osteoarthritis, Knee
12/28
12/28
LR19024 / LG Chem
NCT05237752: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA

Completed
1/2
74
RoW
LG00034053
LG Chem
Osteoarthritis, Knee
12/23
03/24
LR19128 / LG Chem
No trials found
LR19023 / LG Chem
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fotivda (tivozanib) / LG Chem
2021-000050-26: Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Estudio para comparar Tivozanib en combinación con Nivolumab con Tivozanib en monoterapia en sujetos con carcinoma de células renales

Not yet recruiting
3
326
Europe, RoW
Tivozanib, Nivolumab, AV-951, Capsule, hard, Concentrate for solution for infusion, FOTIVDA®, OPDIVO
AVEO Pharmaceuticals, Inc., AVEO PHARMACEUTICALS, INC., AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma Carcinoma de Células Renales, Kidney cancer Cáncer de riñón, Diseases [C] - Cancer [C04]
 
 
TiNivo-2, NCT04987203 / 2021-000050-26: Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Active, not recruiting
3
343
Europe, Canada, US, RoW
Tivozanib, Nivolumab
AVEO Pharmaceuticals, Inc., Parexel, Bristol-Myers Squibb
Renal Cell Carcinoma
04/24
07/26
STRIKE, NCT06661720: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

Recruiting
3
1040
US
Pembrolizumab, Keytruda, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, CT Scan, CAT Scan, Biopsy, Questionnaire Administration
Alliance for Clinical Trials in Oncology
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
11/37
11/37
NCT01885949: Tivozanib + Enzalutamide in Adv Prostate Cancer

Active, not recruiting
2
5
US
Tivozanib, AV-951, Enzalutamide, MDV-3100
Massachusetts General Hospital, National Comprehensive Cancer Network
Prostate Cancer
12/25
06/26
FORTUNE, NCT06053658: Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Recruiting
2
48
US
Tivozanib, KRN 951, KRN-951, KRN951, UNII-172030934T, AV951, AV951 cpd, Nivolumab, Opdivo, BMS-936558
M.D. Anderson Cancer Center, AVEO Pharmaceuticals, Inc.
Renal Cell Carcinoma
11/26
11/28
DEDUCTIVE, NCT03970616: A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

Checkmark 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Jan 2022 - Jan 2022: 1 year OS data from DEDUCTIVE trial in combination with Imfinzi for HCC at ESMO 2022
Hourglass Jan 2021 - Dec 2021 : Data from P2 portion of P1b/2 DEDUCTIVE trial in combination with Imfinzi for advanced HCC
Hourglass Jul 2021 - Dec 2021 : Completion of enrollment of P2 portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC
Checkmark Data from P1b portion of P1b/2 DEDUCTIVE trial in combination with durvalumab for advanced HCC at ASCO GI 2021
More
Terminated
1b/2
27
US
Tivozanib, Fotivda, Durvalumab, Imfinzi
AVEO Pharmaceuticals, Inc., AstraZeneca
Hepatocellular Carcinoma
04/23
04/23
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
06/25
06/26
NCT04645160: Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

Recruiting
1/2
31
US
Tivozanib
National Cancer Institute (NCI)
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
12/26
12/27
Gemiglo (gemigliptin) / Sanofi, LG Chem
NCT05194592: Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 Diabetes

Recruiting
4
122
RoW
Dapagliflozin, Gemigliptin
Wonju Severance Christian Hospital
Type2 Diabetes, Remodeling, Ventricular
12/24
06/25
NCT03842267: A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)

Completed
3
315
RoW
Gemigliptin 50mg, Gemigliptin Placebo
LG Chem
Diabetes Mellitus, Type 2
05/21
11/22
ficlatuzumab (AV-299) / LG Chem
FIERCE-HN, NCT06064877: A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Recruiting
3
410
Europe, Canada, US, RoW
Ficlatuzumab, AV-299, Cetuximab, Erbitux, Placebo
AVEO Pharmaceuticals, Inc.
Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
08/27
11/27
NCT02090127: Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

No Longer Available
N/A
US
ficlatuzumab, AV-299, SCH 900105
AVEO Pharmaceuticals, Inc.
Mullerian Mixed Tumor of Ovary
 
 
TNFcept (etanercept biosimilar) / LG Chem, Mochida
RECAST, NCT05164198: REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis

Not yet recruiting
4
448
NA
Adalimumab and its biosimilars, Humira, Adaloce, Biological: Etanercept and its biosimilars, Enbrel, Eucept, Etalace, Golimumab, Simponi, Infliximab biosimilar, Remsima
Hanyang University Seoul Hospital, Linical Korea
Ankylosing Spondylitis, Axial Spondyloarthritis
10/24
10/24
NCT04449224: Comparative Effectiveness of Targeted Therapy in RA Patients

Recruiting
N/A
506
RoW
Adalimuab, Etanercept, Tocilizumab, or Abatacept, Humira, Enbrel, Etoloche, Eucept, Actemra, or Orencia, Tofacitinib or Baricitinib, Xeljanz or Olumiant
Hanyang University, Ministry of Health, Republic of Korea
Rheumatoid Arthritis
08/23
08/24
Besivo (besifovir) / Gilead, LG Chem, Ildong
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT03642340: A Post-marketing Surveillance to Assess Safety and Efficacy of Besivo

Recruiting
N/A
3000
RoW
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis b
05/23
08/23
Follitrope (recombinant human follicle stimulating hormone) / LG Chem
NCT06921395: Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).

Recruiting
4
248
RoW
Fang Le Shu (Follitrope), Guo Na Fen (Gonal-F)
LG Chem
Female Infertility
09/25
06/26
MSP-IVC, NCT01058252: Minimal Stimulation Protocol Using Aromek(Letrozole) and Follitrope(recFSH) Combined With INVOCell-Low Cost IVF

Recruiting
N/A
30
RoW
INVOCell, Letrozole 2.5 mg, recFSH 75 IU, Aromek (Letrozole 2.5 mg);, Follitrope (Recombinent FSH - 75 IU), IVF-C 5000 IU (HCG), Ova-Surge (Urinary LH Surge Kit), Indomethacin 50 mg, STEP-3: LH Suppression & Monitoring, STEP-4: HCG Timing, IVF-C 5000 IU, STEP-5: OPU, ET, Cancellation, Ovum Pick-Up, Embryo Transfer, Ultrasound Guided, INVOCell (Intravaginal Culturing), INVOCell, Diaphragm (Retention Device)
Galaxy Pharma (Pvt) Limited, Ova IVF & Reproductive Health Clinics, Karachi
Primary Infertility, Secondary Infertility, Low Responders, Mild to Moderate Male Factor Infertility
12/21
03/22
Euforvac (DTwP-HepB) / LG Chem
NCT06413121: Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV

Recruiting
3
1557
RoW
Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV, Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPV
Serum Institute of India Pvt. Ltd.
Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus Influenzae Type B Immunization, Polio Immunization
08/25
05/26
NCT05457946: Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Not yet recruiting
2/3
1438
NA
LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains)
LG Chem
Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type B Infection
09/25
09/25
NCT06690515: Phase I/II, Open Label, Randomized, Safety and Immunogenicity Following DTwP-Hepatitis B-Hib-IPV Vaccine (Bio Farma) in Indonesian Infants

Not yet recruiting
1/2
465
RoW
DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A, DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B, Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®
PT Bio Farma, Faculty of Medicine Universitas Padjadjaran
Vaccine Adverse Reaction, Vaccine Reaction
10/25
09/26
rilogrotug (AV-380) / LG Chem
NCT04815551: A Phase 1 Study of AV-380 in Healthy Subjects

Completed
1
51
US
AV-380, Placebo
AVEO Pharmaceuticals, Inc.
Cachexia
01/22
01/22
NCT05865535: A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia

Recruiting
1
30
US
AV-380
AVEO Pharmaceuticals, Inc.
Cachexia
12/25
06/26
ZemiSU (gemigliptin/glimepiride) / LG Chem
NCT05663736: Effect of Gemigliptin Versus Glimepiride on Cardiac Diastolic Function in Patients With Type 2 Diabetes

Recruiting
4
80
RoW
Gemigliptin, Zemiglo, Glimepiride
Seoul National University Bundang Hospital
Ejection Fraction
10/23
12/23
CUE-101 / Cue Biopharma, LG Chem
NCT04852328: Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

Recruiting
2
30
US
CUE-101
Washington University School of Medicine, Cue Biopharma
Oropharyngeal Squamous Cell Carcinoma
10/27
10/27
KEYNOTE-A78, NCT03978689: A Phase 1 Study in Patients with HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma

Active, not recruiting
1
85
US
CUE-101, KEYTRUDA®, Pembrolizumab, Pembrolizumab
Cue Biopharma, Merck Sharp & Dohme LLC
Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma
01/26
01/26
Hyruan Plus (sodium hyaluronate) / LG Chem
NCT06437054: Verification of the Efficacy/safety of the Mixed Drug Injectable Delivery Vehicle for Treating Intractable Hearing Loss

Not yet recruiting
1/2
26
NA
Dexamethasone, Dexamethasone Inj (Dexamethasone disodium phosphate 5㎎) [Daewon Pharm], Hyaluronic acid, Hyruan Plus Inj (Sodium Hyaluronate 10.0mg) [LG Chem], Indocyanine green(ICG), Cellbiongreen Inj (IndocyanineGreen 25mg) [Cellbion]
Seoul National University Hospital
Hearing Loss, Sensorineural, Hearing Loss, Sudden, Intratympanic Injection
02/26
09/28
Hyruan (sodium hyaluronate) / LG Chem
NCT05220527: Effects of Knee Injections on Patients With Knee Osteoarthritis

Enrolling by invitation
4
60
RoW
Triamcinolone plus hyruan, corticosteroids plus hyaluronic acid, vitagen plus hyruan, dextrose plus hyaluronic acid, normal saline plus hyruan, normal saline plus hyaluronic acid
Taipei Medical University, Shin Kong Wu Ho-Su Memorial Hospital
Knee Osteoarthritis, Injection, Effect of Drug
07/22
07/22
PDC*lung / PDC line Pharma
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

Active, not recruiting
1/2
73
Europe
PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed
PDC*line Pharma SAS
Non Small Cell Lung Cancer
07/24
12/25
tigulixostat (LC350189) / LG Chem
EURELIA1, NCT05586958: Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients

Recruiting
3
350
US
Tigulixostat, LC350189, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
12/24
06/25
EURELIA2, NCT05586971: Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients

Completed
3
2202
US
Tigulixostat, LC350189, Allopurinol, Placebo
LG Chem
Gout, Hyperuricemia, Gout Flare, Tophi
05/25
05/25
NCT06501534: A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Completed
2
84
RoW
Febuxostat, IBI128
Innovent Biologics (Suzhou) Co. Ltd.
Gout, Hyperuricemia
12/24
01/25
NCT06189404: Effect of Tigulixostat on the Pharmacokinetics of Theophylline

Completed
1
24
US
Tigulixostat, LC350189, Theophylline
LG Chem
Gout, Hyperuricemia
11/23
11/23
NCT06277752: A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

Completed
1
30
RoW
dose-5 group, dose-1 group, dose-2 group, dose-4 group, dose-3 group
Innovent Biologics (Suzhou) Co. Ltd.
Gout Arthritis
03/24
03/24
GEN-001 / Genome & Company
GEN001-201, NCT05419362: GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer

Active, not recruiting
2
42
RoW
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/24
KEYNOTE-D86, NCT05998447: GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer

Recruiting
2
148
RoW
GEN-001, Pembrolizumab, KEYTRUDA®, mFOLFOX
Genome & Company, Merck Sharp & Dohme LLC
Biliary Tract Cancer
10/26
10/26
NCT04601402: GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy

Completed
1
11
US
GEN-001, Avelumab, Bavencio
Genome & Company, Merck KGaA, Darmstadt, Germany, Pfizer
Solid Tumor, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma
01/23
01/23
NCT05079503: Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Not yet recruiting
N/A
40
NA
GEN-001, Lactococcus lactis
Korean Cancer Study Group
Locally Advanced Rectal Cancer
08/23
01/24
CUE-102 / Cue Biopharma
CUE-102-01, NCT05360680: A Phase 1 in Patients with HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Completed
1
42
US
CUE-102
Cue Biopharma
Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer
03/25
03/25
NCT06917885: CUE-102 in Recurrent Glioblastoma

Recruiting
1
18
US
CUE-102
David Reardon, MD, Cue Biopharma
Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant
01/26
01/27
LR19122 / LG Chem
NCT06947499: A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Recruiting
2/3
1186
RoW
LBVD, Pentavalent vaccine and Inactivated Polio vaccine
LG Chem
Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b
11/26
04/27
Euvax B (recombinant hepatitis B vaccine) / LG Chem
COMBAT-HBV, NCT05705427: The COMBAT HBV Feasibility Trial

Recruiting
4
560
RoW
Tenofovir Disoproxil Fumarate 300 MG, Viread, Hepatitis B monovalent vaccine, Hepatitis B birth-dose vaccine, Engerix-B, Placebo
University of North Carolina, Chapel Hill, Doris Duke Charitable Foundation, Université Protestant au Congo, Abbott, Albert Einstein College of Medicine
Hepatitis B, Vertical Transmission of Infectious Disease
08/25
08/25
MIT-001 / MitoImmune Therap
Capella, NCT05493800: Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT

Active, not recruiting
2
60
RoW
MIT-001, normal saline, placebo
MitoImmune Therapeutics
Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
06/24
12/24
MIT-001, NCT04651634: for Prevention of CCRT-Induced OM in HNSCC Patients

Active, not recruiting
2
60
US, RoW
MIT-001 plus CCRT
MitoImmune Therapeutics
Head and Neck Squamous Cell Carcinoma, Oral Mucositis
12/25
12/25
NCT05389696: Clinical Trial to Evaluate Pharmacokinetic Characteristics of MIT-001 After SC Administration in Healthy Subjects

Completed
1
40
RoW
Single subcutaneous administration and Blood collection, MIT-001 10mg and 20mg, Single subcutaneous administration and then IV injection., MIT-001 40mg, MIT-001 20mg and 40mg_Multiple administration, MIT-001 20mg and 40mg
MitoImmune Therapeutics
Heathly Subjects
02/23
04/23
ICM-203 / Yonsei Technology Holdings
NCT04875754: A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

Active, not recruiting
1/2
16
RoW
ICM-203, Placebo
ICM Biotech Australia Pty Ltd.
Osteoarthritis, Knee
03/26
12/26
NCT05454566: A Study Evaluating the Safety, Tolerability, and Activity of ICM-203 in Subjects With Knee Osteoarthritis.

Not yet recruiting
1/2
18
NA
ICM-203
ICM Co. Ltd.
Osteoarthritis, Knee
05/26
11/27
NCT05752032: A Long Term Follow-up Study of Subjects Who Received ICM-203 or Matching Placebo

Enrolling by invitation
N/A
16
RoW
ICM-203, Placebo
ICM Co. Ltd.
Osteoarthritis, Knee
12/28
12/28
LR19024 / LG Chem
NCT05237752: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA

Completed
1/2
74
RoW
LG00034053
LG Chem
Osteoarthritis, Knee
12/23
03/24
LR19128 / LG Chem
No trials found
LR19023 / LG Chem
No trials found

Download Options